Pharmacy Practice and Science Department Highlights: February 2022
(February 1, 2022)
Publications
Shared Gene Expression and Immune Pathway Changes Associated with Progression from Nevi to Melanoma. Cancers 2022, 14, 3.
- Borden, E.
- Adams, A.
- Buetow, K.
- Wilson, M.
- Bauman, J.
- Curiel-Lewandrowski, C.
- Chow, H.
- Bonnie LaFleur, PhD
- Hastings, K.
Early oral switch to combined cefixime therapy for management of osteoarticular infections in pediatric sickle cell disease patients: a descriptive analysis. Journal of Infection and Public Health 2022;15:1-6.
- Mohzari, Y.
- Alshuraim, R.
- Asdaq, S.
- Aljobair, F.
- Alrashed, A.
- Alsowaida, Y.
- Alamer, A.
- Al Munjem, M.
- Al Musawa, M.
- Hatata, M.
- Alzaaqi, M.
- Binrokan, A.
- Alajlan, S.
- Ivo Abraham, PhD, RN
- Alamer, A.
Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients. Future Oncology 2022;18:363-373
- McBride, A.
- Alrawashdh, N.
- MacDonald, K.
- Ivo Abraham, PhD, RN
Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy. Journal of Medical Economics 2021;24(Suppl 1):71-83.
- Ivo Abraham, PhD, RN
- Onyekwere, U.
- Deniz, B.
- Moran, D.
- Chioda, M.
- MacDonald, K.
- Huang, H.
Economic evaluation using dynamic transition modeling of ebola virus vaccination in lower-and-middle-income countries. Journal of Medical Economics 2021;24(Suppl 1):1-13.
- Obeng-Kusi, M.
- Habila, M.
- Roe, D.
- Brian Erstad, PharmD, MCCM, FCCP, FASHP
- Ivo Abraham, PhD, RN
Economic evaluation of polatuzumab-bendamustine-rituximab vs tafasitamab-lenalidomide in transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma using classical and novel metrics. Journal of Medical Economics 2021;24(Suppl 1):14-24.
- Calamia, M.
- McBride, A.
- Ivo Abraham, PhD, RN
Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities. Journal of Medical Economics 2021;24(Suppl 1):34-41.
- Choi, B.
- Abraham, R.
- Halawah, H.
- Calamia, M.
- Obeng-Kusi, M.
- Alrawashdh, N.
- Arku, D.
- Ivo Abraham, PhD, RN
Is there still a role for talimogene laherparepvec (T-VEC)? An indirect efficacy comparison of T-VEC plus ipilimumab combination therapy versus T-VEC alone as salvage therapy in unresectable metastatic melanoma. Expert Opinion on Biological Therapy 2021;21:1647-1653
- Maryam Fazel, BCPS, BCACP, CDE
- Alrawashdh, N.
- Alamer, A.
- Curiel-Lewandrowski, C.
- Ivo Abraham, PhD, RN
Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to FOLFIRINOX treatment for metastatic pancreatic cancer. Future Oncology 2021;17:4561-4570
- MacDonald, K.
- Alrawashdh, N.
- McBride, A.
- Ivo Abraham, PhD, RN
Far Upstream Binding Protein 1 Participates in Translational Control of Nrf2 Protein Under Oxidative Stress Redox Biology 2021 May; 41:101906.
- Dai, W.
- Zhang, J.
- Qu, H.
- Thongkum, A.
- Qin Chen, PhD
Nrf2 for Cardiac Protection: Pharmacological Options Against Oxidative Stress Trends Pharmcol Sci. 2021 Sept 42(9): 729-744
N-Acetylcysteine for Cardiac Protection during Coronary Artery Reperfusion: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front. Cardiovasc. Med. Nov 19, 2021.
- Khan, S.
- Campbell, A.
- Lu, Y.
- An, L.
- Alpert, J.
- Qin Chen, PhD
Randomized Pilot Trial on Optimal Treatment Strategy, Myocardial Change, and Prognosis of Patients with Myocardial Infarction with Nonobstructive Coronary Artery (MINOCA) Am J Med 135 (1): 103-109. Jan 1, 2022
- Serpytis, R.
- Majauskiene, E.
- Navickas, P.
- Lizaitis, M.
- Glaveckaite, S.
- Rucinskas, K.
- Petrulioniene, Z.
- Valeviciene, N.
- Samalavicius, R.
- Berukstis, A.
- Baranauskas, A.
- Gargalskaite, U.
- Laucevicius, A.
- Qin Chen, PhD
- Alpert, J.
- Serpytis, P.
Nrf2 for Protection Against Oxidant Generation and Mitochondrial Damage in Cardiac Injury Free Radical Biol. Med. 179, Feb 2022, 133-143
Nrf2 Signaling in Heart Failure: Expression of Nrf2, Keap1, Antioxidant and Detoxification Genes in Dilated or Ischemic Cardiomyopathy Physiol. Genomics, (In press)
- Lu, Y.
- An, L.
- Taylor, M.
- Qin Chen, PhD
The Essential Research Curriculum for Doctor of Pharmacy Degree Programs: 2021 Update. J Am Coll Clin Pharm. 2022 [In Press]
- Jason Karnes, PharmD, PhD, BCPS, FAHA
- Asempa, T.
- Barreto, J.
- Belcher, R.
- Bissell, B.
- Gamma, R.
- Kier, K.
- Lee, C.
- Liu, L.
- McCune, J.
- Minhaj, F.
- Newsome, A.
- Ning, J.,
- Bookstaver, P.
Elucidation of Cellular Contributions to Heparin-Induced Thrombocytopenia Using Omic Approaches. Front Pharmacol. 2022 [In Press]
- Giles, J.
- Miller, E.
- Steiner, H.
- Jason Karnes, PharmD, PhD, BCPS, FAHA
PharmGKB Summary: Heparin Induced Thrombocytopenia (HIT) Pathway. Pharmacogenet Genomics. 2022 [In Press]
- Miller, E.
- Norwood, C.
- Giles, J.
- Huddart, R.
- Jason Karnes, PharmD, PhD, BCPS, FAHA
- Whirl-Carrillo, M.
- Klein, T.
Presentations
Qin Chen, PhD gave the following two invited talks on Precision Medicine of Heart Failure to: 7th Meeting on Acute Cardiology and Emergency Medicine in Vilnius, Lithuania (Sept, 2021) and Moscow Cardiology Congress in Moscow, Russia (Oct, 2021).
Kudos
Nancy Alvarez, PharmD, BCPS was elected to a three-year term on the Board of Directors for the American Institute for the History of Pharmacy.
Bonnie LaFleur, PhD is co-I on a newly funded DoD grant with Kathy Rodgers (Associate Director, Translational Neuroscience, Center for Innovations in Brain Science and Professor, Pharmacology) to study " Biomarker Development for the Evaluation of Mas Agonist, RASRx1902, in Amyotrophic Lateral Sclerosis.”